...
首页> 外文期刊>Gynecologic Oncology: An International Journal >Definitive intensity-modulated radiation therapy with concurrent chemotherapy for patients with locally advanced cervical cancer.
【24h】

Definitive intensity-modulated radiation therapy with concurrent chemotherapy for patients with locally advanced cervical cancer.

机译:局部晚期宫颈癌患者的确定性强度调制放疗与同步化疗。

获取原文
获取原文并翻译 | 示例

摘要

OBJECTIVE: Cervical cancer is one of the most common cancers diagnosed in women worldwide. Concurrent chemoradiotherapy (CCRT) is the mainstay treatment for locally advanced cervical cancer. The purpose of this study was to investigate the treatment outcomes and toxicity of definitive intensity-modulated radiotherapy (IMRT) with concurrent chemotherapy for patients with locally advanced carcinoma of the cervix in a single institution. METHODS: Between January 2004 and November 2008, 109 patients with stage IB2-IVA cervical carcinoma treated with IMRT and concurrent cisplatin-based chemotherapy were evaluated retrospectively. All patients received external irradiation of 45-54 Gy with an IMRT technique. High dose rate brachytherapy of 20-33.5 Gy was prescribed to point A as a local boost. Each patient received concurrent cisplatin-based chemotherapy monthly or weekly. The endpoints were overall survival (OS), local failure-free survival (LFFS) and disease-free survival (DFS). Patients were assessed for acute toxicity weekly according to the Common Toxicity Criteria for Adverse Events (CTCAE), version 3.0. Late toxicity was evaluated according to RTOG-EORTC Late Radiation Morbidity Scoring Schema. RESULTS: The median follow up time for all surviving patients was 32.5 months, with a range from 5 to 75 months. The 3-year OS, LFFS and DFS were 78.2%, 78.1% and 67.6%, respectively. Three (2.7%) patients developed grade 3 or greater acute gastrointestinal (GI) toxicity and 26 (23.9%) patients developed grade 3 or greater hematological toxicity. Five (4.6%) patients developed grade 3 or greater chronic GI toxicity and 7 (6.4%) patients developed grade 3 or greater genitourinary system toxicity. CONCLUSIONS: Good outcomes were achieved with definitive IMRT and concurrent chemotherapy for patients with locally advanced cervical cancer and the combined treatment was well tolerated with favorable acute and late toxicity.
机译:目的:宫颈癌是全世界女性中最常见的癌症之一。同步放化疗是局部晚期宫颈癌的主要治疗手段。这项研究的目的是在单一机构中研究确定性调强放疗(IMRT)与同时化疗对子宫颈局部晚期癌患者的治疗结果和毒性。方法:回顾性分析2004年1月至2008年11月期间接受IMRT和顺铂联合化疗的109例IB2-IVA期宫颈癌患者的临床资料。所有患者均接受了IMRT技术的45-54 Gy外部照射。 A点开具20-33.5 Gy的高剂量近距离放射疗法作为局部加强。每名患者每月或每周接受基于顺铂的同步化疗。终点为总体生存期(OS),局部无故障生存期(LFFS)和无疾病生存期(DFS)。每周根据《不良事件通用毒性标准》(CTCAE)3.0版对患者进行急性毒性评估。根据RTOG-EORTC晚期辐射发病率评分方案评估晚期毒性。结果:所有幸存患者的中位随访时间为32.5个月,范围为5到75个月。 3年OS,LFFS和DFS分别为78.2%,78.1%和67.6%。 3名(2.7%)患者发展为3级或更高的急性胃肠道(GI)毒性,26名(23.9%)患者发展为3级或更高的血液学毒性。 5名(4.6%)患者发展为3级或更高的慢性胃肠道毒性,7名(6.4%)患者发展为3级或更高的泌尿生殖系统毒性。结论:明确的IMRT和同步化疗对局部晚期宫颈癌患者取得了良好的疗效,联合治疗耐受性良好,具有良好的急性和晚期毒性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号